Key Financial’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$83K Hold
450
– – 0.01% 457
2026
Q2
$110K Hold
450
– – 0.02% 402
2026
Q1
$76.1K Hold
450
– – 0.01% 454
2025
Q4
$82.2K Hold
450
– – 0.02% 427
2025
Q3
$53.4K Hold
450
– – 0.01% 507
2025
Q2
$47K Hold
450
– – 0.01% 504
2025
Q1
$52.5K Hold
450
– – 0.01% 473
2024
Q4
$38.1K Hold
450
– – 0.01% 524
2024
Q3
$40.4K Hold
450
– – 0.01% 513
2024
Q2
$36.2K Hold
450
– – 0.01% 521
2024
Q1
$35.9K Hold
450
– – 0.01% 491
2023
Q4
$35.8K Hold
450
– – 0.01% 483
2023
Q3
$31.4K Hold
450
– – 0.01% 481
2023
Q2
$32.3K Hold
450
– – 0.01% 478
2023
Q1
$27.8K Hold
450
– – 0.01% 475
2022
Q4
$20.1K Hold
450
– – 0.01% 493
2022
Q3
$20K Hold
450
– – 0.01% 494
2022
Q2
$18K Hold
450
– – 0.01% 522
2022
Q1
$19K Hold
450
– – 0.01% 506
2021
Q4
$17K Sell
450
-1,000
-69% -$36.8K 0.01% 509
2021
Q3
$48K Buy
+1,450
New +$56.5K 0.03% 348

Other funds holding AXSM

Key Financial's AXSM Position: Q3 2026 in Review

Key Financial held its Axsome Therapeutics (AXSM) position steady in Q3 2026 at 450 shares worth $83K. The position accounts for 0.01% of the portfolio, ranked #457.

Key Financial first reported a position in AXSM in Q3 2021 and has held it in 21 quarters since. The position peaked at $110K in Q2 2026. 348 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • Key Financial held 450 shares of Axsome Therapeutics worth $83K as of Q3 2026.
  • Key Financial left its Axsome Therapeutics share count unchanged in Q3 2026.
  • Axsome Therapeutics made up 0.01% of Key Financial's portfolio in Q3 2026, its #457 holding.
  • Key Financial first reported a position in Axsome Therapeutics in Q3 2021 and has held it in 21 quarters since.
  • Key Financial's Axsome Therapeutics position peaked at $110K in Q2 2026.
  • 348 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Key Financial's 13F filing for Q3 2026, filed 2 Nov 2026.